12:51 PM EDT, 04/02/2025 (MT Newswires) -- A US approval of Novavax's ( NVAX ) COVID-19 vaccine is in limbo after the Food and Drug Administration missed a deadline for a full approval of the treatment, The Wall Street Journal reported Wednesday.

The FDA previously allowed emergency use of Novavax's ( NVAX ) vaccine and the agency's decision would have determined whether to grant the vaccine a normal, full approval, the report said, citing people familiar with the matter.

Novavax's ( NVAX ) application is still reportedly pending and could be approved by the agency at any time, the sources said.

Novavax ( NVAX ) and the FDA did not immediately respond to requests for comment from MT Newswires.

NVAX shares were up 3% in recent trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 6.18, Change: +0.18, Percent Change: +3.02